MCID: SBS004
MIFTS: 51

Substance Dependence

Categories: Mental diseases

Aliases & Classifications for Substance Dependence

MalaCards integrated aliases for Substance Dependence:

Name: Substance Dependence 12 55 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9973
NCIt 50 C35458

Summaries for Substance Dependence

Disease Ontology : 12 A substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance.

MalaCards based summary : Substance Dependence is related to drug dependence and depression. An important gene associated with Substance Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Transmission across Chemical Synapses. The drugs Dopamine and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Substance dependence, also known as drug dependence, is an adaptive state that develops from repeated... more...

Related Diseases for Substance Dependence

Diseases related to Substance Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 drug dependence 30.9 BDNF CNR1 DRD2 DRD3 OPRD1 OPRK1
2 depression 30.6 BDNF MAOA SLC6A4
3 smoking as a quantitative trait locus 3 30.0 CHRNA3 CHRNA5
4 borderline personality disorder 30.0 BDNF HTR1B MAOA SLC6A4
5 personality disorder 30.0 BDNF DRD2 DRD4 HTR1B MAOA SLC6A3
6 antisocial personality disorder 30.0 DRD2 HTR1B MAOA SLC6A3 SLC6A4
7 anxiety 29.9 BDNF CNR1 MAOA SLC6A4
8 bulimia nervosa 29.9 BDNF HTR1B SLC6A4
9 conduct disorder 29.7 DRD2 DRD4 DRD5 MAOA SLC6A3 SLC6A4
10 eating disorder 29.7 BDNF CNR1 DRD2 POMC SLC6A3 SLC6A4
11 psychotic disorder 29.6 BDNF DRD2 DRD3 DRD4 SLC6A3 SLC6A4
12 generalized anxiety disorder 29.4 BDNF DRD2 MAOA SLC6A4
13 post-traumatic stress disorder 29.3 BDNF CNR1 DRD2 MAOA SLC6A4
14 panic disorder 29.3 BDNF MAOA POMC SLC6A4
15 bipolar disorder 29.3 BDNF DRD2 DRD3 DRD4 DRD5 MAOA
16 tobacco addiction 29.3 CHRNA3 CHRNA5 CHRNB4 DRD2 MAOA OPRM1
17 pathological gambling 29.1 DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
18 disease of mental health 28.9 BDNF CNR1 DRD2 DRD3 DRD4 MAOA
19 substance abuse 28.8 BDNF DRD2 DRD3 DRD4 DRD5 HTR1B
20 attention deficit-hyperactivity disorder 28.8 BDNF DRD2 DRD3 DRD4 DRD5 HTR1B
21 mood disorder 28.7 BDNF DRD2 DRD3 DRD4 HTR1B MAOA
22 alcohol abuse 28.7 BDNF CNR1 DRD2 DRD3 DRD4 SLC6A4
23 schizophrenia 28.7 BDNF CNR1 DRD2 DRD3 DRD4 DRD5
24 cocaine dependence 28.5 CHRNA3 CHRNA5 DRD2 DRD3 OPRD1 OPRK1
25 alcohol dependence 28.2 ADH4 BDNF CNR1 DRD2 DRD3 DRD4
26 cyclic vomiting syndrome 10.3 CNR1 OPRM1
27 neonatal abstinence syndrome 10.3 OPRD1 OPRK1 OPRM1
28 morphine dependence 10.2 OPRD1 OPRK1 OPRM1
29 opioid addiction 10.2 DRD2 OPRD1 OPRK1 OPRM1
30 early-onset schizophrenia 10.2 BDNF DRD2
31 withdrawal disorder 10.2 CNR1 OPRM1 POMC
32 cannabis abuse 10.2 BDNF CNR1
33 pain agnosia 10.2 CNR1 OPRK1 OPRM1 POMC
34 agnosia 10.2 CNR1 OPRK1 OPRM1 POMC
35 uremic pruritus 10.2 CNR1 OPRK1
36 alexithymia 10.1
37 separation anxiety disorder 10.1 DRD4 OPRM1 SLC6A3
38 alcohol-induced mental disorder 10.1 DRD2 SLC6A3 SLC6A4
39 alcoholic psychosis 10.1 DRD2 SLC6A3 SLC6A4
40 tic disorder 10.1 DRD2 DRD4 DRD5 SLC6A3
41 social phobia 10.0 DRD2 MAOA SLC6A4
42 childhood disintegrative disease 10.0 BDNF POMC
43 phobic disorder 10.0 MAOA OPRK1 SLC6A4
44 cocaine abuse 10.0 DRD2 SLC6A3 SLC6A4
45 avoidant personality disorder 10.0 MAOA SLC6A4
46 agoraphobia 10.0 MAOA OPRK1 SLC6A4
47 atypical depressive disorder 10.0 MAOA SLC6A4
48 premature ejaculation 10.0 HTR1B SLC6A3 SLC6A4
49 polysubstance abuse 10.0 CNR1 DRD2 DRD3
50 retrograde amnesia 10.0 POMC SLC6A4

Graphical network of the top 20 diseases related to Substance Dependence:



Diseases related to Substance Dependence

Symptoms & Phenotypes for Substance Dependence

GenomeRNAi Phenotypes related to Substance Dependence according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.03 MAOA
2 Decreased viability GR00381-A-1 10.03 ADH4 SLC6A4
3 Decreased viability GR00381-A-3 10.03 SLC6A4
4 Decreased viability GR00402-S-2 10.03 ADH1A ADH4 BDNF CHRNA3 CHRNA5 CHRNB4
5 no effect GR00402-S-1 9.62 ADH1A ADH4 BDNF CHRNA3 CHRNA5 CHRNB4

MGI Mouse Phenotypes related to Substance Dependence:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BDNF CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
2 homeostasis/metabolism MP:0005376 10.21 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
3 growth/size/body region MP:0005378 10.14 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
4 endocrine/exocrine gland MP:0005379 10.09 BDNF DRD2 DRD5 HTR1B OPRK1 OPRM1
5 digestive/alimentary MP:0005381 10.06 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
6 nervous system MP:0003631 10.06 BDNF CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
7 mortality/aging MP:0010768 10.03 BDNF CHRNA3 CHRNB4 CNR1 DRD2 DRD3
8 integument MP:0010771 10.02 BDNF CHRNB4 CNR1 DRD2 OPRD1 OPRK1
9 adipose tissue MP:0005375 9.97 CNR1 DRD2 DRD3 HTR1B OPRM1 POMC
10 no phenotypic analysis MP:0003012 9.56 BDNF CHRNA3 CNR1 DRD2 HTR1B OPRD1
11 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Substance Dependence

Drugs for Substance Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
2
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
3
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
4
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 52485-79-7 40400 644073
6
Naloxone Approved, Vet_approved Phase 4,Not Applicable 465-65-6 5284596
7
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 50-36-2 5760 446220
8
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-11-5 942 89594
9
Bupropion Approved Phase 4,Phase 2,Not Applicable 34841-39-9, 34911-55-2 444
10
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 300-62-9 5826 3007
11
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
12
Ribavirin Approved Phase 4 36791-04-5 37542
13
Methadone Approved Phase 4,Phase 3,Phase 1,Not Applicable 76-99-3 4095
14
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
15
Allopurinol Approved Phase 4 315-30-0 2094
16
Choline Approved, Nutraceutical Phase 4,Not Applicable 62-49-7 305
17
Heroin Illicit, Investigational Phase 4,Phase 1 561-27-3 5462328
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Analgesics, Opioid Phase 4,Phase 3,Phase 1,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Analgesics Phase 4,Phase 3,Phase 1,Not Applicable
27 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
34 Serotonin Agents Phase 4,Phase 3,Phase 2
35 Antidepressive Agents Phase 4,Phase 2
36 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
37 Antidepressive Agents, Second-Generation Phase 4,Phase 2
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
39 Serotonin Uptake Inhibitors Phase 4,Phase 3
40 Lisdexamfetamine Dimesylate Phase 4,Phase 1,Phase 2
41 GABA Agents Phase 4,Phase 2
42 Tranquilizing Agents Phase 4,Phase 3,Phase 2
43 Anticonvulsants Phase 4,Phase 2
44 Antimanic Agents Phase 4
45 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
46 Buprenorphine, Naloxone Drug Combination Phase 4,Not Applicable
47 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1,Not Applicable
48 Cytidine Diphosphate Choline Phase 4,Not Applicable
49 Anesthetics, Local Phase 4,Phase 2,Phase 1,Not Applicable
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
2 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4 Vyvanse
3 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
4 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
5 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
6 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
7 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
8 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
9 Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial Terminated NCT00461890 Phase 4 Injectable Naltrexone
10 Allopurinol Maintenance Study for Bipolar Disorder Terminated NCT00732251 Phase 4 Allopurinol
11 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Withdrawn NCT01155544 Phase 4
12 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices Completed NCT00657397 Phase 3 Methadone
13 Adolescent Outpatient and Continuing Care Study Completed NCT01381133 Phase 3
14 Maternal Acupuncture for Substance Abuse Completed NCT00225316 Phase 3
15 Incentive Programs for Female Substance Abusers Who Smoke - 3 Completed NCT00064922 Phase 2, Phase 3
16 Addiction Health Evaluation And Disease Management (AHEAD) Study Completed NCT00278447 Phase 3
17 A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR) Completed NCT01620996 Phase 3
18 Olanzapine Treatment of Patients With Bipolar I Disorder Completed NCT00510146 Phase 3 Olanzapine;Placebo
19 Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland Completed NCT01100853 Phase 3 VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
20 RCT Comparing Methadone and Buprenorphine in Pregnant Women Completed NCT00271219 Phase 3 Methadone;Buprenorphine
21 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
22 Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
23 Evaluation of Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates Unknown status NCT01378923 Phase 1, Phase 2
24 A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1 Unknown status NCT00033124 Phase 2
25 Memory Reconsolidation Blockade for Treating Drug Addiction Completed NCT01634347 Phase 2 Propranolol and memory reactivation;Placebo and memory reactivation
26 Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment Completed NCT01410110 Phase 2
27 Group Therapy for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
28 Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients Completed NCT00295139 Phase 2
29 D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals Completed NCT00780442 Phase 2 D-cycloserine;Placebo
30 Atomoxetine for the Treatment of Cannabis Dependence Completed NCT00167297 Phase 2 Atomoxetine
31 The MEADOW PROJECT (Mending the Effects of Alcohol and Depression on Women) and The Bridge Program (Connecting Recovery Treatment and Behavioral Health) Completed NCT00851669 Phase 2
32 Psychopharmacology for Cocaine Dependence - Buspirone Completed NCT01267292 Phase 2 Buspirone;Placebo for Buspirone;Methylphenidate;Placebo for Methylphenidate
33 Validating Interventions for Diverse Adolescents Completed NCT01018654 Phase 2
34 Efficacy Trial of Warrior Check-Up Completed NCT01128140 Phase 2
35 Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment Completed NCT00288886 Phase 2
36 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
37 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
38 VIVITROL as a Treatment for Cocaine and Alcohol Dependence Completed NCT00777062 Phase 2 VIVITROL (Naltrexone extended-release injectable suspension);Placebo
39 Bupropion for the Treatment of Methamphetamine Dependence - 1 Completed NCT00069251 Phase 2 Bupropion
40 Ondansetron for the Treatment of Methamphetamine Dependence - 1 Completed NCT00040053 Phase 2 Ondansetron
41 Topiramate for the Treatment of Methamphetamine Dependence - 1 Completed NCT00345371 Phase 2 Topiramate;Placebo Oral Tablet
42 Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence Completed NCT00520286 Phase 2 Modafinil;Placebo
43 Vigabatrin for Treatment of Cocaine Dependence Completed NCT00611130 Phase 2 vigabatrin;placebo
44 Distress Tolerance Treatment for Substance Users Recruiting NCT01741415 Phase 2
45 Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use Terminated NCT00430573 Phase 2 D-cycloserine;Placebo
46 Relapse Prevention Study in Newly Abstinent Smokers Withdrawn NCT00793468 Phase 2 GSK598809;Nicotine Replacement Transdermal Patch;Placebo
47 "The Evaluation of Stimulant Withdrawal" Withdrawn NCT00442923 Phase 2 Coreg
48 Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence Unknown status NCT02052258 Phase 1 Oxytocin
49 To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334 Completed NCT00513279 Phase 1 GSK618334;GSK618334 matching placebo tablets
50 Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809 Completed NCT00437632 Phase 1 GSK598809;Placebo;Caffeine

Search NIH Clinical Center for Substance Dependence

Genetic Tests for Substance Dependence

Anatomical Context for Substance Dependence

MalaCards organs/tissues related to Substance Dependence:

41
Brain, Testes, Cortex, Bone, Eye, Cingulate Cortex

Publications for Substance Dependence

Articles related to Substance Dependence:

(show top 50) (show all 391)
# Title Authors Year
1
Nurse Anesthetists' Reflections on Caring for Patients With Previous Substance Dependence: Balancing Between Professionalism and Preconceptions. ( 29362049 )
2018
2
Corrigendum to "Mindfulness-oriented recovery enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial" [Behav. Res. Ther. 77 (2016) 7-16]. ( 28964403 )
2018
3
Effects of acute exercise on drug craving, self-esteem, mood and affect in adults with poly-substance dependence: Feasibility and preliminary findings. ( 29869351 )
2018
4
Evaluation of previous substance dependence genome-wide significant findings in a Spanish sample. ( 29715653 )
2018
5
Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. ( 29034725 )
2018
6
Efficacy and Safety of Atypical Antipsychotics in Bipolar Disorder With Comorbid Substance Dependence: A Systematic Review. ( 30036197 )
2018
7
Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence. ( 30482645 )
2018
8
Mega-Analysis of Gray Matter Volume in Substance Dependence: General and Substance-Specific Regional Effects. ( 30336705 )
2018
9
Abuse and Effects of Salvia divinorum in a Sample of Patients Hospitalized for Substance Dependence. ( 30374761 )
2018
10
Early childhood maltreatment experience and later sexual behavior in Brazilian adults undergoing treatment for substance dependence. ( 30540023 )
2018
11
The effects of patient and physician characteristics on early outpatient satisfaction with substance dependence care: results of the SUBUSQOL study. ( 28507432 )
2017
12
Development of a Contextualized Version of the Multiple Errands Test for People with Substance Dependence. ( 29041993 )
2017
13
Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms. ( 27997065 )
2017
14
Behavioral approach and orbitofrontal cortical activity during decision-making in substance dependence. ( 28934666 )
2017
15
Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. ( 28847449 )
2017
16
Patient experiences questionnaire for interdisciplinary treatment for substance dependence (PEQ-ITSD): reliability and validity following a national survey in Norway. ( 28219361 )
2017
17
Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. ( 28211594 )
2017
18
Quality measurers of therapeutic communities for substance dependence: an international collaborative study survey in Latin America. ( 29262838 )
2017
19
Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence. ( 28956341 )
2017
20
Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence. ( 28445303 )
2017
21
Which adolescents develop persistent substance dependence in adulthood? Using population-representative longitudinal data to inform universal risk assessment. ( 26620720 )
2016
22
Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. ( 27093128 )
2016
23
Use of Family CAGE-AID questionnaire to screen the family members for diagnosis of substance dependence. ( 27748296 )
2016
24
Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity. ( 27854264 )
2016
25
Cytokine mediated changes of pain sensitivity in predisposition to substance dependence. ( 29244477 )
2016
26
A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. ( 27733137 )
2016
27
An association study revealed substantial effects of dominance, epistasis and substance dependence co-morbidity on alcohol dependence symptom count. ( 27151647 )
2016
28
Attention deficit hyperactivity disorder symptoms, type of offending and recidivism in a prison population: The role of substance dependence. ( 27455899 )
2016
29
Associations between compulsive buying and substance dependence/abuse, major depressive episodes, and generalized anxiety disorder among men and women. ( 27215919 )
2016
30
Comorbid depression, antisocial personality, and substance dependence: Relationship with delay discounting. ( 26846198 )
2016
31
Mindfulness-Oriented Recovery Enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial. ( 26701171 )
2016
32
Disturbing sleep and sleepfulness during recovery from substance dependence in residential rehabilitation settings. ( 27917494 )
2016
33
The Positive and Negative Syndrome Scale (PANSS): A Three-Factor Model of Psychopathology in Marginally Housed Persons with Substance Dependence and Psychiatric Illness. ( 26999280 )
2016
34
Does Emotion Dysregulation Mediate the Relationship between Early Maltreatment and Later Substance Dependence? Findings of the CANSAS Study. ( 27438781 )
2016
35
Lifetime history of traumatic events in a young adult Mexican American sample: Relation to substance dependence, affective disorder, acculturation stress, and PTSD. ( 27569652 )
2016
36
Women with comorbid substance dependence and psychiatric disorders in Sweden: a longitudinal study of hospital care utilization and costs. ( 26048811 )
2015
37
Relationship between drug dreams, affect, and craving during treatment for substance dependence. ( 25700139 )
2015
38
The Comorbid and Individual Impacts of Maternal Depression and Substance Dependence on Parenting and Child Behavior Problems. ( 26478656 )
2015
39
Medical diagnoses associated with substance dependence among inpatients at a large urban hospital. ( 26107402 )
2015
40
Alcohol-Dependent Subjects Show Different Personality Traits Compared With Subjects With Multiple Substance Dependence: Preliminary Data. ( 26079976 )
2015
41
Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection. ( 26298399 )
2015
42
Investigating the factor structure of the Illness Perception Questionnaire-revised for substance dependence among injecting drug users in China. ( 25649986 )
2015
43
Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. ( 26392368 )
2015
44
Impaired Decision-Making, Higher Impulsivity, and Drug Severity in Substance Dependence and Pathological Gambling. ( 25918968 )
2015
45
Temperament and character dimensions assessed in general population, in individuals with psychoactive substance dependence and in young male conscripts. ( 25687735 )
2015
46
Reward salience and risk aversion underlie differential ACC activity in substance dependence. ( 26106528 )
2015
47
Dissecting ancestry genomic background in substance dependence genome-wide association studies. ( 26267224 )
2015
48
A Pilot Study of Seeking Safety in a Sample of German Women Outpatients with Substance Dependence and Posttraumatic Stress Disorder. ( 26514284 )
2015
49
Effectiveness of Computer-Assisted Therapy for Substance Dependence Using Breaking Free Online: Subgroup Analyses of a Heterogeneous Sample of Service Users. ( 26543918 )
2015
50
Emergency department use and hospitalizations among homeless adults with substance dependence and mental disorders. ( 26242968 )
2015

Variations for Substance Dependence

Expression for Substance Dependence

Search GEO for disease gene expression data for Substance Dependence.

Pathways for Substance Dependence

Pathways related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 ADH1A ADH4 CNR1 DRD2 DRD3 DRD4
2
Show member pathways
12.84 CHRNA3 CHRNA5 CHRNB4 MAOA SLC6A3 SLC6A4
3
Show member pathways
12.7 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
4
Show member pathways
12.67 BDNF DRD2 DRD3 DRD4 DRD5
5
Show member pathways
12.48 CHRNA3 CHRNB4 DRD2 DRD3 DRD4 DRD5
6 12.21 DRD2 DRD3 DRD4 DRD5
8
Show member pathways
12.13 BDNF DRD2 DRD5 HTR1B
9 12.01 BDNF CHRNB4 MAOA SLC6A4
10 11.85 HTR1B MAOA SLC6A4
11
Show member pathways
11.83 BDNF DRD2 MAOA SLC6A3
12 11.79 CNR1 DRD3 DRD4
13 11.79 MAOA OPRD1 OPRM1 POMC
14
Show member pathways
11.72 DRD2 DRD3 DRD4 DRD5 HTR1B
15
Show member pathways
11.69 CHRNA3 CHRNA5 CHRNB4
16
Show member pathways
11.63 ADH1A ADH4 MAOA
17
Show member pathways
11.56 CHRNA3 CHRNA5 DRD2 DRD3 DRD4
18
Show member pathways
11.29 MAOA SLC6A3 SLC6A4
19 11.03 HTR1B MAOA SLC6A4
20
Show member pathways
10.96 MAOA SLC6A3 SLC6A4
21 10.84 DRD2 DRD3 DRD5
22
Show member pathways
10.77 ADH4 MAOA
23
Show member pathways
10.45 CHRNA3 CHRNB4

GO Terms for Substance Dependence

Cellular components related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.93 CHRNA3 CHRNA5 CHRNB4 SLC6A3 SLC6A4
2 axon GO:0030424 9.91 BDNF CNR1 DRD2 OPRM1 SLC6A3
3 dendrite GO:0030425 9.87 BDNF CHRNA3 DRD2 DRD4 HTR1B OPRK1
4 postsynaptic membrane GO:0045211 9.86 CHRNA3 CHRNA5 CHRNB4 OPRD1
5 membrane raft GO:0045121 9.85 CNR1 OPRD1 OPRM1 SLC6A3 SLC6A4
6 integral component of plasma membrane GO:0005887 9.8 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
7 GABA-ergic synapse GO:0098982 9.72 CNR1 DRD2 DRD3
8 axon terminus GO:0043679 9.7 DRD2 OPRD1 OPRK1
9 integral component of postsynaptic membrane GO:0099055 9.65 DRD2 OPRK1 OPRM1 SLC6A3 SLC6A4
10 acetylcholine-gated channel complex GO:0005892 9.58 CHRNA3 CHRNA5 CHRNB4
11 spine apparatus GO:0097444 9.49 OPRD1 OPRM1
12 serotonergic synapse GO:0099154 9.48 HTR1B SLC6A4
13 dopaminergic synapse GO:0098691 9.46 CHRNA5 DRD2 DRD3 SLC6A3
14 integral component of presynaptic membrane GO:0099056 9.23 CNR1 DRD2 HTR1B OPRD1 OPRK1 OPRM1
15 membrane GO:0016020 10.44 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
16 integral component of membrane GO:0016021 10.31 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
17 plasma membrane GO:0005886 10.24 ADH1A CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2

Biological processes related to Substance Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.95 OPRD1 OPRK1 OPRM1 POMC
2 chemical synaptic transmission GO:0007268 9.95 CHRNA3 CHRNA5 CHRNB4 DRD4 DRD5 HTR1B
3 regulation of membrane potential GO:0042391 9.92 CHRNA3 CHRNA5 CHRNB4
4 cellular calcium ion homeostasis GO:0006874 9.91 DRD3 DRD4 DRD5
5 memory GO:0007613 9.9 BDNF CNR1 SLC6A4
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.9 HTR1B OPRD1 OPRK1 OPRM1
7 excitatory postsynaptic potential GO:0060079 9.89 CHRNA3 CHRNA5 CHRNB4 DRD2 OPRM1
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.88 OPRD1 OPRK1 OPRM1
9 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.88 CNR1 DRD2 DRD3
10 sensory perception of pain GO:0019233 9.87 CNR1 OPRK1 OPRM1
11 nervous system process GO:0050877 9.87 CHRNA3 CHRNA5 CHRNB4
12 social behavior GO:0035176 9.87 DRD3 DRD4 SLC6A4
13 regulation of synaptic vesicle exocytosis GO:2000300 9.86 CHRNA5 DRD2 HTR1B
14 response to amphetamine GO:0001975 9.84 DRD2 DRD3 DRD4 DRD5
15 neuromuscular synaptic transmission GO:0007274 9.83 CHRNA3 CHRNA5 CHRNB4
16 regulation of sensory perception of pain GO:0051930 9.83 OPRD1 OPRK1 OPRM1
17 negative regulation of blood pressure GO:0045776 9.83 CNR1 DRD2 DRD3 DRD5
18 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.83 CNR1 DRD4 HTR1B OPRD1 OPRM1
19 arachidonic acid secretion GO:0050482 9.82 DRD2 DRD3 DRD4
20 eating behavior GO:0042755 9.81 OPRD1 OPRK1 OPRM1
21 synaptic transmission, cholinergic GO:0007271 9.81 CHRNA3 CHRNA5 CHRNB4
22 dopamine receptor signaling pathway GO:0007212 9.8 DRD2 DRD3 DRD4
23 negative regulation of protein secretion GO:0050709 9.8 DRD2 DRD3 DRD4
24 response to ethanol GO:0045471 9.8 CNR1 DRD2 DRD3 HTR1B OPRK1 OPRM1
25 synaptic transmission, dopaminergic GO:0001963 9.79 DRD2 DRD3 DRD5
26 dopamine metabolic process GO:0042417 9.79 DRD2 DRD3 DRD4
27 prepulse inhibition GO:0060134 9.78 DRD2 DRD3 SLC6A3
28 G protein-coupled receptor internalization GO:0002031 9.77 DRD2 DRD3 HTR1B
29 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.76 DRD3 DRD5 OPRM1
30 behavioral response to cocaine GO:0048148 9.76 DRD2 DRD3 DRD4 OPRK1
31 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.75 DRD2 DRD3
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.75 DRD2 DRD3 DRD4
33 regulation of smooth muscle contraction GO:0006940 9.74 CHRNA3 CHRNB4
34 response to iron ion GO:0010039 9.74 DRD2 SLC6A3
35 vasoconstriction GO:0042310 9.74 HTR1B SLC6A4
36 estrous cycle GO:0044849 9.74 OPRK1 OPRM1
37 behavioral response to ethanol GO:0048149 9.74 DRD2 DRD4 OPRM1
38 neurotransmitter biosynthetic process GO:0042136 9.73 SLC6A3 SLC6A4
39 positive regulation of renal sodium excretion GO:0035815 9.73 DRD2 DRD3
40 regulation of synaptic transmission, GABAergic GO:0032228 9.73 CNR1 DRD2
41 ethanol oxidation GO:0006069 9.73 ADH1A ADH4
42 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.73 DRD3 DRD4
43 opioid receptor signaling pathway GO:0038003 9.73 OPRD1 OPRK1 OPRM1
44 regulation of dopamine metabolic process GO:0042053 9.72 DRD4 SLC6A3
45 sensory perception GO:0007600 9.72 OPRK1 OPRM1
46 adenohypophysis development GO:0021984 9.72 DRD2 SLC6A3
47 behavior GO:0007610 9.72 HTR1B OPRK1
48 monoamine transport GO:0015844 9.72 SLC6A3 SLC6A4
49 behavioral response to nicotine GO:0035095 9.72 CHRNA3 CHRNA5 CHRNB4
50 response to morphine GO:0043278 9.72 CNR1 DRD2 DRD3 OPRK1 OPRM1

Molecular functions related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 CNR1 DRD2 DRD3 DRD4 DRD5 HTR1B
2 extracellular ligand-gated ion channel activity GO:0005230 9.69 CHRNA3 CHRNA5 CHRNB4
3 ligand-gated ion channel activity GO:0015276 9.67 CHRNA3 CHRNA5 CHRNB4
4 neuropeptide binding GO:0042923 9.65 OPRD1 OPRK1 OPRM1
5 acetylcholine binding GO:0042166 9.63 CHRNA3 CHRNA5 CHRNB4
6 acetylcholine-gated cation-selective channel activity GO:0022848 9.61 CHRNA3 CHRNA5 CHRNB4
7 retinol dehydrogenase activity GO:0004745 9.59 ADH1A ADH4
8 adrenergic receptor activity GO:0004935 9.58 DRD2 DRD3
9 neurotransmitter:sodium symporter activity GO:0005328 9.58 SLC6A3 SLC6A4
10 acetylcholine receptor activity GO:0015464 9.58 CHRNA3 CHRNA5 CHRNB4
11 serotonin binding GO:0051378 9.57 HTR1B SLC6A4
12 alcohol dehydrogenase (NAD) activity GO:0004022 9.56 ADH1A ADH4
13 monoamine transmembrane transporter activity GO:0008504 9.55 SLC6A3 SLC6A4
14 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.54 ADH1A ADH4
15 opioid receptor activity GO:0004985 9.54 OPRD1 OPRK1 OPRM1
16 receptor serine/threonine kinase binding GO:0033612 9.52 OPRD1 OPRK1
17 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.5 DRD2 DRD3 DRD4
18 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD3 DRD4 DRD5
19 dopamine binding GO:0035240 9.35 DRD2 DRD3 DRD4 DRD5 SLC6A3
20 drug binding GO:0008144 9.17 CHRNB4 CNR1 DRD2 DRD3 DRD4 HTR1B

Sources for Substance Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....